MiPet Benazapet 20 mg Tablets for Dogs

In double-blind clinical trials in dogs with congestive heart failure, benazepril
hydrochloride was well tolerated with an incidence of adverse reactions lower
than observed in placebo-treated dogs. A small number of dogs may exhibit
transient vomiting, incoordination or signs of fatigue. On rare occasions
diarrhoea and anorexia have been reported in dogs.
In dogs with chronic kidney disease, MiPet Benazapet may increase plasma
creatinine concentrations at the start of therapy. A moderate increase in plasma
creatinine concentrations following administration of ACE inhibitors is
compatible with the reduction in glomerular hypertension induced by these
agents, and is therefore not necessarily a reason to stop therapy in the absence
of other signs.
'The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse
reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)

Revised: December 2025
MA split from NI Expiry following AN: 02088/2025
- very rare (less than 1 animal in 10,000 animals treated, including isolated
reports).